Bausch Health Companies Inc. Increase (Decrease) in Deferred Revenue
Bausch Health Companies Inc. (BHC) reported Increase (Decrease) in Deferred Revenue of $280.00 thousand for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2012-05-04
- Bausch Health Companies Inc. increase (decrease) in deferred revenue for the quarter ending 2012-03-31 was $280.00K, a 74.10% decline year-over-year.
- Bausch Health Companies Inc. increase (decrease) in deferred revenue for the quarter ending 2011-12-31 was -$2.58M.
- Bausch Health Companies Inc. increase (decrease) in deferred revenue for the quarter ending 2011-09-30 was -$587.00K.
- Bausch Health Companies Inc. increase (decrease) in deferred revenue for the quarter ending 2011-06-30 was -$1.54M, a 311.37% decline year-over-year.
- Bausch Health Companies Inc. increase (decrease) in deferred revenue for fiscal 2011 was -$3.63M.
- Bausch Health Companies Inc. increase (decrease) in deferred revenue for fiscal 2010 was -$2.82M.
- Bausch Health Companies Inc. increase (decrease) in deferred revenue for fiscal 2009 was -$13.11M.
- Bausch Health Companies Inc. increase (decrease) in deferred revenue for fiscal 2008 was -$11.11M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2012-03-31 | $280.00K 10-Q · filed 2012-05-04 | -$2.30M derived: sum of 2 quarters · filed 2012-05-04 | -$2.89M derived: sum of 3 quarters · filed 2012-05-04 | -$4.43M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-12-31 | -$2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$3.17M derived: sum of 2 quarters · filed 2012-02-29 | -$4.71M derived: sum of 3 quarters · filed 2012-02-29 | -$3.63M 10-K · filed 2012-02-29 |
| 2011-09-30 | -$587.00K 10-Q · filed 2011-11-04 | -$2.13M derived: sum of 2 quarters · filed 2011-11-04 | -$1.05M 10-Q · filed 2011-11-04 | -$3.11M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-06-30 | -$1.54M 10-Q · filed 2011-08-08 | -$462.00K 10-Q · filed 2011-08-08 | -$2.52M derived: sum of 3 quarters · filed 2012-05-04 | -$2.54M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-03-31 | $1.08M 10-Q · filed 2012-05-04 | -$978.00K derived: sum of 2 quarters · filed 2012-05-04 | -$996.00K derived: sum of 3 quarters · filed 2012-05-04 | -$266.00K derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | -$2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$2.08M derived: sum of 2 quarters · filed 2012-02-29 | -$1.35M derived: sum of 3 quarters · filed 2012-02-29 | -$2.82M 10-K · filed 2012-02-29 |
| 2010-09-30 | -$18.00K 10-Q · filed 2011-11-04 | $712.00K derived: sum of 2 quarters · filed 2011-11-04 | -$758.00K 10-Q · filed 2011-11-04 | -$6.79M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $730.00K 10-Q · filed 2011-08-08 | -$740.00K 10-Q · filed 2011-08-08 | -$6.77M derived: sum of 3 quarters · filed 2012-02-29 | -$4.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | -$1.47M 10-Q · filed 2011-05-10 | -$7.50M derived: sum of 2 quarters · filed 2012-02-29 | -$4.73M derived: sum of 3 quarters · filed 2012-02-29 | -$6.75M derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | -$6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$3.26M derived: sum of 2 quarters · filed 2012-02-29 | -$5.28M derived: sum of 3 quarters · filed 2012-02-29 | -$13.11M 10-K · filed 2012-02-29 |
| 2009-09-30 | $2.77M 10-Q · filed 2010-11-05 | $753.00K derived: sum of 2 quarters · filed 2010-11-05 | -$7.07M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | -$2.02M 10-Q · filed 2010-08-06 | -$9.85M 10-Q · filed 2010-08-06 | ||
| 2008-12-31 | -$11.11M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |